Newron Pharmaceuticals bags up to €38 million to fuel Phase III ENIGMA-TRS program
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
The enhancements will improve environmental sustainability, strengthen material governance, and boost utility reliability
The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore
Subscribe To Our Newsletter & Stay Updated